Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab in Bullous Pemphigoid
NCT04465292Phase 1Unknown
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of tildrakizumab in Bullous Pemphigoid (BP), sponsored by Brigham and Women's Hospital. Primary endpoint: Change in Disease Severity at 24 weeks. Status: unknown.
02
Drugs
tildrakizumab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT04465292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04465292.